Abstract
Thromboembolic disorders are a major cause of morbidity and mortality in industrialized countries. For prophylaxis of thrombosis at present the so-called indirect anticoagulants of the dicoumarol type, the biopolymer heparin and several antiplatelet drugs are used. The active principle of the medicinal leech, hirudin, is available now as a recombinant product and is being tested clinically. Each of the mentioned anticoagulants has its values and limitations, based either on the chemical nature or on the mode of action. Antithrombotic regimes that do not interfere with the coagulation system are proposed; their value, however, has not yet been fully documented.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
